Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.9
5.2
Journals
Vaccines
Special Issues
A One-Health Perspective on Immunization Against Infectious Diseases
share announcement

A One-Health Perspective on Immunization Against Infectious Diseases

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccines against Tropical and other Infectious Diseases".

Deadline for manuscript submissions: 30 June 2025 | Viewed by 2263

Special Issue Editor

Dr. Jose Camilla Sammartino

E-Mail Website
Guest Editor
Department of Clinical-Surgical, Diagnostic and Pediatric Sciences, Università degli Studi di Pavia, Pavia, Italy
Interests: infectious diseases; emerging and re-emerging pathogens; immune response; cellular virology; clinical microbiology; immunofluorescence

Special Issue Information

Dear Colleagues,

Various factors, including climate change, overpopulation, migration, and globalization, have increased the spread of pandemic potential. Vaccination is the primary method for achieving herd immunity, protecting vulnerable populations, and controlling and eradicating infectious agents. While vaccination requires time to mount a durable response, therapeutic options can bridge the vaccine gap. Monoclonal antibodies provide immediate protection, especially when there are no therapeutic options. We are pleased to invite you to contribute to our Special Issue, entitled “A One-Health Perspective on Immunization against Infectious Diseases”. This Special Issue explores the various factors involved in developing immunization strategies against emerging and well-known infectious microorganisms. We encourage the submission of original research articles, methodological papers, and reviews focusing on the interplay between human, animal, and environmental factors, as well as how these interactions affect population immunization. Additionally, we welcome discussions on when active or passive immunization strategies may be favorable.

The scope of this Special Issue is to promote knowledge at the One-Health level, encompassing the medical, veterinary, and environmental sciences. Research areas may include, but are not limited to, the following topics:

  • Vaccine and therapeutic antibody development;
  • Characterization of immune-escaping mechanisms;
  • Identification of disease resistance;
  • Methodologies for sustainable immunization strategies;
  • Preclinical and clinical studies that evaluate innate and/or adaptive immunity, therapeutics and vaccination, and immunization strategies for immunocompromised individuals;
  • The human–animal–environment interface.

We look forward to receiving your contributions.

Dr. Jose Camilla Sammartino
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • One-Health vaccinology
  • immunization
  • vaccine
  • antibody
  • infectious disease
  • emerging pathogens
  • climate change
  • sustainability

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

14 pages, 2109 KiB  
Article
Safety and Immunogenicity of the Attenuated Yellow Fever Vaccine in Several Neotropical Primate Species
by Nayara Ferreira de Paula, André Duarte Vieira, Daniel Oliveira dos Santos, Lucas dos Reis de Souza, Carlyle Mendes Coelho, Herlandes Penha Tinoco, Paula Cristina Senra Lima, Rafael Otávio Cançado Motta, Valéria do Socorro Pereira, Marcelo Pires Nogueira de Carvalho, Camilla Bayma Fernandes, Adriana de Souza Azevedo, Matheus Soares Arruda, Thais Alkifeles Costa, Betania Paiva Drumond, Fabiola de Oliveira Paes Leme, Marcos da Silva Freire, Tatiane Alves da Paixão, Ayisa Rodrigues Oliveira and Renato Lima Santos
Vaccines 2025, 13(5), 487; https://doi.org/10.3390/vaccines13050487 - 30 Apr 2025
Viewed by 68
Abstract
Background/Objective: Yellow fever (YF) is an acute infectious disease caused by the yellow fever virus which is transmitted by mosquitoes. Neotropical primates are susceptible to infection, which is often presented as epizootic outbreaks. The aim was to evaluate and characterize the immune response [...] Read more.
Background/Objective: Yellow fever (YF) is an acute infectious disease caused by the yellow fever virus which is transmitted by mosquitoes. Neotropical primates are susceptible to infection, which is often presented as epizootic outbreaks. The aim was to evaluate and characterize the immune response against YF in different species of neotropical primates from the Belo Horizonte Zoo. Methods: Vaccine 17DD was administered to 24 neotropical primates, with a single subcutaneous dose. Clinical exams, RNAemia, and detection of IgG and neutralizing antibodies against YFV were performed. In addition, an ethogram was performed to assess clinical changes and animal welfare. Results: At 4 days post-vaccination, RNAemia was detected in nine animals. There was seroconversion and persistence of immune response in Alouatta guariba clamitans, Sapajus xanthosternos, Saguinus imperator and Aotus infulatus. However, the vaccine was not immunogenic for Lagothrix cana. In Pithecia irrorata seroconversion did not persist long term, while the Ateles sp. had a transient immune response. No significant clinical manifestations were observed in any of the vaccinated animals. Conclusions: This study demonstrated a safe, immunogenic and persistent immune response induced by the attenuated 17DD vaccine strain in A. guariba clamitans, S. xanthosternos, S. imperator, and A. infulatus. Full article
(This article belongs to the Special Issue A One-Health Perspective on Immunization Against Infectious Diseases)
►▼ Show Figures

Figure 1

17 pages, 3795 KiB  
Article
Cell-Free Screening, Production and Animal Testing of a STI-Related Chlamydial Major Outer Membrane Protein Supported in Nanolipoproteins
by Mariam Mohagheghi, Abisola Abisoye-Ogunniyan, Angela C. Evans, Alexander E. Peterson, Gregory A. Bude, Steven Hoang-Phou, Byron Dillon Vannest, Dominique Hall, Amy Rasley, Dina R. Weilhammer, Nicholas O. Fischer, Wei He, Beverly V. Robinson, Sukumar Pal, Anatoli Slepenkin, Luis de la Maza and Matthew A. Coleman
Vaccines 2024, 12(11), 1246; https://doi.org/10.3390/vaccines12111246 - 1 Nov 2024
Viewed by 1298
Abstract
Background: Vaccine development against Chlamydia, a prevalent sexually transmitted infection (STI), is imperative due to its global public health impact. However, significant challenges arise in the production of effective subunit vaccines based on recombinant protein antigens, particularly with membrane proteins like the Major [...] Read more.
Background: Vaccine development against Chlamydia, a prevalent sexually transmitted infection (STI), is imperative due to its global public health impact. However, significant challenges arise in the production of effective subunit vaccines based on recombinant protein antigens, particularly with membrane proteins like the Major Outer Membrane Protein (MOMP). Methods: Cell-free protein synthesis (CFPS) technology is an attractive approach to address these challenges as a method of high-throughput membrane protein and protein complex production coupled with nanolipoprotein particles (NLPs). NLPs provide a supporting scaffold while allowing easy adjuvant addition during formulation. Over the last decade, we have been working toward the production and characterization of MOMP-NLP complexes for vaccine testing. Results: The work presented here highlights the expression and biophysical analyses, including transmission electron microscopy (TEM) and dynamic light scattering (DLS), which confirm the formation and functionality of MOMP-NLP complexes for use in animal studies. Moreover, immunization studies in preclinical models compare the past and present protective efficacy of MOMP-NLP formulations, particularly when co-adjuvanted with CpG and FSL1. Conclusion: Ex vivo assessments further highlight the immunomodulatory effects of MOMP-NLP vaccinations, emphasizing their potential to elicit robust immune responses. However, further research is warranted to optimize vaccine formulations further, validate efficacy against Chlamydia trachomatis, and better understand the underlying mechanisms of immune response. Full article
(This article belongs to the Special Issue A One-Health Perspective on Immunization Against Infectious Diseases)
►▼ Show Figures

Figure 1

Review

Jump to: Research

36 pages, 3120 KiB  
Review
Viral Infections in Elderly Individuals: A Comprehensive Overview of SARS-CoV-2 and Influenza Susceptibility, Pathogenesis, and Clinical Treatment Strategies
by Yanhao Huang, Shumin Li, Wenjie Ye, Haoyun Wang, Jun Su, Lijuan Gao, Ruohu Shi, Xinyi Mou, Sean Xiao Leng, Chanchan Xiao and Guobing Chen
Vaccines 2025, 13(4), 431; https://doi.org/10.3390/vaccines13040431 - 21 Apr 2025
Viewed by 442
Abstract
As age increases, the immune function of elderly individuals gradually decreases, increasing their susceptibility to infectious diseases. Therefore, further research on common viral infections in the elderly population, especially severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza viruses, is crucial for scientific [...] Read more.
As age increases, the immune function of elderly individuals gradually decreases, increasing their susceptibility to infectious diseases. Therefore, further research on common viral infections in the elderly population, especially severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza viruses, is crucial for scientific progress. This review delves into the genetic structure, infection mechanisms, and impact of coinfections with these two viruses and provides a detailed analysis of the reasons for the increased susceptibility of elderly individuals to dual viral infections. We evaluated the clinical manifestations in elderly individuals following coinfections, including complications in the respiratory, gastrointestinal, nervous, and cardiovascular systems. Ultimately, we have summarized the current strategies for the prevention, diagnosis, and treatment of SARS-CoV-2 and influenza coinfections in older adults. Through these studies, we aim to reduce the risk of dual infections in elderly individuals and provide a scientific basis for the prevention, diagnosis, and treatment of age-related viral diseases, thereby improving their health status. Full article
(This article belongs to the Special Issue A One-Health Perspective on Immunization Against Infectious Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop